Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Urology. 2019 May 25;131:176–183. doi: 10.1016/j.urology.2019.05.012

Figure 2. Geographic Distribution of Urologists Who Are Moderate-High Prescribers of Abiraterone and Enzalutamide.

Figure 2

Geographic distribution of urologists who are moderate-high prescribers of abiraterone (top panels) in 2013 and 2016 and moderate-high prescribers of enzalutamide (bottom panels) in 2013 and 2016, demonstrating the increase in urologists prescribing these therapies. Moderate prescribers prescribed > 10 prescriptions in a year for abiraterone or enzalutamide but to 10 or fewer beneficiaries total. High prescribers prescribed abiraterone or enzalutamide to greater than 10 beneficiaries total in the year.